|Summary sheet: Clonidine|
|Common names||Catapres, Catapres-TTS, Kapvay, Nexiclon XR|
|Routes of Administration|
Clonidine (known by the trade names Catapres, Kapvay, Nexiclon, Clophelin, and others) is an antihypertensive medication that has depressant and focus enhancing properties. It is primarily used to treat high blood pressure, but can also be used for a variety of conditions that include attention deficit hyperactivity disorder, anxiety disorders, tic disorders, substance withdrawal, migraine, diarrhea, and certain pain conditions.
Developed by Boehringer Ingelheim for its blood pressure effects, clonidine first saw clinical use in 1966. As the first anti-hypertensive agent with a clearly identifiable central site of action, clonidine has been an important pharmacological tool in discovering the role of central α-adrenoceptors in the physiology of central blood pressure regulation.
Clonidine is classified as a centrally acting α2 adrenergic agonist and imidazoline receptor agonist. Its activity on the α2 receptors in the brainstem inhibits the release of norepinephrine (NE), resulting in decreased sympathetic nervous system tone.
Clonidine has several off-label uses. It has been prescribed to treat psychiatric disorders including stress, sleep disorders, and hyperarousal caused by post-traumatic stress disorder, borderline personality disorder, and other anxiety disorders.
- 1 History and culture
- 2 Chemistry
- 3 Pharmacology
- 4 Subjective effects
- 5 Toxicity and harm potential
- 6 Legal status
- 7 See also
- 8 External links
- 9 Literature
- 10 References
History and culture
In the early 1960s, the medicinal chemist Helmut Stähle was tasked by Boehringer Ingelheim with synthesizing a peripherally active a-adrenergic compound that would be useful for nasal decongestion as simple nose drops. A locally acting a-adrenergic vasoconstrictor agent was expected to provide relief from the symptoms of the common cold by shrinking the swollen nasal membranes and producing an unobstructed air passage.
The synthetic design of clonidine was achieved when Stähle had the idea of substituting two chlorine groups on the phenyl group of the imidazoline structure, which most of the newer decongestive agents at the time were derived from. At that time, a double halogen substitution was still unusual for pharmaceuticals, and the prevailing opinion was that compounds with several halogen atoms would at best be useful as pesticides. Despite this, clonidine was pursued and discovered to have a remarkably high vasoconstrictive and decongestive effect at an unusually low dosage level.
The decongestive effects were then determined by nasal cavity tests on anesthetized dogs. After the first trial in humans, it became clear that clonidine's decongestant properties were far less interesting than its potent anti-hypertensive effects. The compound was then developed for this new indication and was introduced into therapy in 1966 under the trade name Catapres, where it saw widespread use.
With the discovery of clonidine, the central a-adrenergic receptors first became known to chemists, pharmacologists and physicians. It has been an important pharmacological tool in researching the role of central α-adrenoceptors in the physiology of central blood pressure regulation and nervous system function.
In the 2010s, the US Food and Drug Administration (FDA) approved clonidine, both alone or with stimulants, for the treatment of attention deficit hyperactivity disorder (ADHD) in pediatric and adult patients. In Australia, clonidine is an accepted but not approved use for ADHD by the TGA.
Clonidine, or 2-[(2,6-Dichlorophenyl)imino]imidazoline, is a compound of the imidazoline chemical class. Imidazolines are substituted amidines in which the amidine function is incorporated into an imidazoline ring. This portion is connected to an aromatic nucleus by way of a methylene bridge.
Additionally, two chlorine atoms are substituted in the 2- and 6-positions of the phenyl ring. This addition has the critical effect of making the molecule sufficiently lipophilic to penetrate the blood-brain barrier.
Other compounds of this class include the a-adrenergic agents tolazoline, naphazoline, and phentolamine. The a-adrenergic effects of clonidine and other imidazolidine compounds may be explained on the basis of a structural overlap between clonidine and norepinephrine.
Clonidine is an agonist for the α2 adrenergic receptor. When α2 receptors in the brain are stimulated, peripheral vascular resistance decreases, resulting in lowered blood pressure. It has specificity towards the presynaptic α2 receptors in the vasomotor center in the brainstem. This binding decreases presynaptic calcium levels and inhibits the release of norepinephrine (NE). The net effect is a decrease in sympathetic nervous system tone.
Three G-protein coupled α2-receptor subtypes have been identified: α2A, α2B, and α2C. Each subtype has a unique pattern of tissue distribution in the central nervous system and peripheral tissues. The α2A-receptor is widely distributed throughout the central nervous system; it is found in the locus coeruleus, brain stem nuclei, cerebral cortex, septum, hypothalamus, and hippocampus. α2A receptors are also expressed in the kidneys, spleen, thymus, lung and salivary glands. The α2C-receptor is primarily expressed in the central nervous system, including the striatum, olfactory tubercle, hippocampus and cerebral cortex. The α2B receptor is located primarily in the periphery (kidney, liver, lung and heart).
The α2A- and α2C receptors are located presynaptically and inhibit the released of noradrenaline from sympathetic nerves. Stimulation of these receptors decreases sympathetic tone, resulting in decreases in blood pressure and heart rate. Sedation and analgesia is mediated by centrally located α2A receptors, while peripheral α2B receptors mediate constriction of vascular smooth muscle. α2A receptors also mediate essential components of the analgesic effect of nitrous oxide in the spinal cord. Clonidine stimulates all three α2 receptor subtypes with similar potency.
Clonidine also has peripheral α1 agonist activity.
|Binding Sites||Binding Affinity Ki (nM)|
Clonidine is rapidly absorbed from the gastrointestinal tract and has excellent CNS penetration because of lipid solubility. Peak plasma concentrations are reached 3-5 hours after a single oral dose. No known pharmacologically active metabolites exist. Plasma half-life is 12-16 hours, with the antihypertensive effects occurring within 30-60 minutes of ingestion. Clonidine is excreted unchanged in the urine and is metabolized by the liver.
The effects listed below are based upon the subjective effects index and personal experiences of PsychonautWiki contributors. The listed effects should be taken with a grain of salt and will rarely (if ever) occur all at once, but heavier doses will increase the chances and are more likely to induce a full range of effects. Likewise, adverse effects become much more likely on higher doses and may include serious injury or death.
- Sedation - Clonidine can produce a strong sedative effect, which has been compared to that of benzodiazepines. Users can become very tired and sleep through prompts to awake.
- Decreased heart rate
- Decreased blood pressure - Clonidine's sympatholytic effects quickly and effectively lowers blood pressure. Users should take care to avoid standing up too quickly to avoid an overwhelming light-headedness and possible fainting spell.
- Abnormal heartbeat - This effect has a low likelihood. Caution should be taken if clonidine is taken with other substances that affect heartbeat. Intense physical activity should be avoided while on this substance.
- Dry mouth
- Physical fatigue
- Dizziness - This effect can increase the likelihood of falling and injuring oneself.
- Raynaud's Phenomenon - Raynaud's Phenomenon occurs when the spasm of arteries results in reduced blood flow to the extremities, causing a pale tone, tingling, coldness, and numbness.
- Cognitive fatigue
- Addiction suppression - Clonidine has shown efficacy as a treatment for alcohol, opioid, and nicotine substance use disorders. It has been shown to block opiate withdrawal symptoms.
- Anxiety suppression - Clonidine has mild to moderate anxiolytic effects and is sometimes used clinically to treat anxiety.
- Focus enhancement - This effect usually occurs at lower doses which are sometimes prescribed for the treatment of ADHD.
- Focus suppression - This effect usually occurs at higher doses.
- Memory enhancement
- Thought deceleration
- Auditory suppression - Reports describe this effect as a "hollow" loss of hearing. It is believed to be a result of lowered blood pressure.
- Irritability - One can feel very agitated and annoyed, especially with more ease. This especially happens when the medicine is suddenly stopped, which is an incorrect practice; clonidine should be tapered off of the user.
- Increased heart rate - This occurs as a rebound effect to clonidine's antihypertensive effects and is typically only prominent following sustained use.
- Increased blood pressure - This occurs as a rebound effect to clonidine's antihypertensive effects and is typically only prominent following sustained use.
There are currently 1 anecdotal reports which describe the effects of this compound within our experience index.
Additional experience reports can be found here:
Toxicity and harm potential
At therapeutic doses (0.2-0.9 mg/d), clonidine is commonly associated with adverse effects such as dry mouth, sedation, dizziness, and constipation. While generally safe, at toxic doses clonidine can cause serious cardiopulmonary instability and central nervous system (CNS) depression in children and adults. Caution should be used when clonidine is taken with other depressants.
It is strongly recommended that one use harm reduction practices when using this substance.
The oral LD50 for clonidine in mice is 206 mg/kg and for rats, 465 mg/kg. In humans, lethality is rare with a small number of reported deaths. Morbidity, in terms of cardiorespiratory and CNS dysfunction, generally tends to be more severe in young persons than in adults.
Symptoms of clonidine overdose include constriction of pupils of the eye, drowsiness, high blood pressure followed by a drop in pressure, irritability, low body temperature, slowed breathing, slowed heartbeat, slowed reflexes, and weakness.
Tolerance and addiction potential
Clonidine is not addictive and has a low potential for abuse. The chronic use of clonidine can produce physical dependence and withdrawal symptoms if one suddenly stops their usage. Clonidine therapy should generally be gradually tapered when discontinuing therapy to avoid rebound hypertension from occurring.
Although clonidine is not considered to be addictive, cases of misuse have been documented among certain groups with pre-existing substance use disorders. It is sometimes used in combination with opiates to extend and potentiate their effects. This practice may increase the risk of oversedation and respiratory depression associated with opioid use.
Although many psychoactive substances are safe on their own, they can become dangerous and even life-threatening when combined with other substances. The list below contains some common potentially dangerous combinations, but may not include all of them. Certain combinations may be safe in low doses of each but still increase the potential risk of death. Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.
- Depressants (alcohol, benzodiazepines, thienodiazepines, barbiturates, GHB/GBL, methaqualone, opioids) - This combination can result in dangerous or even fatal levels of respiratory depression. These substances potentiate the muscle relaxation and sedation caused by one another and can lead to unexpected loss of consciousness at high doses. There is also an increased risk of vomiting during unconsciousness and death from the resulting suffocation. If this occurs, users should attempt to fall asleep in the recovery position or have a friend move them into it.
- Stimulants (lisdexamfetamine, amphetamine, propylhexedrine) - This combination increases the likelihood of an abnormal heartbeat. Caution should be exercised and physical activity should be avoided. However, in clinical settings, this combination may be used to treat ADHD due to its positive effects on focus or memory.
This legality section is a stub.
As such, it may contain incomplete or wrong information. You can help by expanding it.
United States: Clonidine is only available with a prescription.
- Stähle, H. (2000). A historical perspective: development of clonidine. Best Practice & Research Clinical Anaesthesiology, 14(2), 237-246. https://doi.org/10.1053/bean.2000.007
- Brayfield, A, ed. (13 January 2014). "Clonidine". Martindale: The Complete Drug Reference. London, UK: Pharmaceutical Press. Retrieved 28 June 2014.
- Stähle, H. (2000). A historical perspective: development of clonidine. Best Practice & Research Clinical Anaesthesiology, 14(2), 237-246. https://doi.org/10.1053/bean.2000.0079
- Neil, MJ (November 2011). "Clonidine: clinical pharmacology and therapeutic use in pain management". Current Clinical Pharmacology. 6 (4): 280–7. https://doi.org/10.2174/157488411798375886. PMID 21827389.
- Shen, Howard (2008). Illustrated Pharmacology Memory Cards: PharMnemonics. Minireview. p. 12. ISBN 1-59541-101-1.
- van der Kolk, BA (September–October 1987). "The drug treatment of post-traumatic stress disorder". Journal of Affective Disorders. 13 (2): 203–13. doi:10.1016/0165-0327(87)90024-3. PMID 2960712.
- Sutherland, SM; Davidson, JR (June 1994). "Pharmacotherapy for post-traumatic stress disorder". The Psychiatric Clinics of North America. 17 (2): 409–23. PMID 7937367.
- Southwick, SM; Bremner, JD; Rasmusson, A; Morgan CA, 3rd; Arnsten, A; Charney, DS (November 1999). "Role of norepinephrine in the pathophysiology and treatment of posttraumatic stress disorder". Biological Psychiatry. 46 (9): 1192–204. doi:10.1016/S0006-3223(99)00219-X. PMID 10560025.
- Strawn, JR; Geracioti, TD, Jr (2008). "Noradrenergic dysfunction and the psychopharmacology of posttraumatic stress disorder". Depression and Anxiety. 25 (3): 260–71. doi:10.1002/da.20292. PMID 17354267.
- Boehnlein, JK; Kinzie, JD (March 2007). "Pharmacologic reduction of CNS noradrenergic activity in PTSD: the case for clonidine and prazosin". Journal of Psychiatric Practice. 13 (2): 72–8. doi:10.1097/01.pra.0000265763.79753.c1. PMID 17414682.
- Huffman, JC; Stern, TA (2007). "Neuropsychiatric consequences of cardiovascular medications". Dialogues in Clinical Neuroscience. 9 (1): 29–45. PMC . PMID 17506224.
- Najjar, F; Weller, RA; Weisbrot, J; Weller, EB (April 2008). "Post-traumatic stress disorder and its treatment in children and adolescents". Current Psychiatry Reports. 10 (2): 104–8. doi:10.1007/s11920-008-0019-0. PMID 18474199.
- Ziegenhorn, AA; Roepke, S; Schommer, NC; Merkl, A; Danker-Hopfe, H; Perschel, FH; Heuser, I; Anghelescu, IG; Lammers, CH (April 2009). "Clonidine improves hyperarousal in borderline personality disorder with or without comorbid posttraumatic stress disorder: a randomized, double-blind, placebo-controlled trial". Journal of Clinical Psychopharmacology. 29 (2): 170–3. doi:10.1097/JCP.0b013e31819a4bae. PMID 19512980.
- Rossi, S, ed. (2013). Australian Medicines Handbook (2013 ed.). Adelaide: The Australian Medicines Handbook Unit Trust. ISBN 978-0-9805790-9-3.
- Sullivan, P. A., De Quattro, V., Foti, A. N. D. R. A. S., & Curzon, G. (1986). Effects of clonidine on central and peripheral nerve tone in primary hypertension. Hypertension, 8(7), 611-617. PMID: 3721561
- Bricca, G., Greney, H., Zhang, J., Dontenwill, M., Stutzmann, J., Belcourt, A., & Bousquet, P. (1994). Human brain imidazoline receptors: further characterization with [3 H] clonidine. European Journal of Pharmacology: Molecular Pharmacology, 266(1), 25-33. DOI: https://doi.org/10.1016/0922-4106(94)90205-4
- Reis, D. J.; Piletz, J. E. (1997). "The imidazoline receptor in control of blood pressure by clonidine and drugs" (pdf). American Journal of Physiology. 273 (5): R1569–R1571. PMID 9374795.
- Roth, BL; Driscol, J (12 January 2011). "PDSP Ki Database". Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. Archived from the original on 8 November 2013. Retrieved 25 November 2013.
- Mitchell A, Bührmann S, Opazo Saez A, Rushentsova U, Schäfers RF, Philipp T, et al. Clonidine lowers blood pressure by reducing vascular resistance and cardiac output in young, healthy males. Cardiovasc Drugs Ther 2005;19:49–55. pmid:15883756
- Gold, M., Redmond Jr, D. E., & Kleber, H. (1978). Clonidine blocks acute opiate-withdrawal symptoms. The Lancet, 312(8090), 599-602. https://doi.org/10.1016/S0140-6736(78)92823-4
- Hoehn-Saric R, Merchant AF, Keyser ML, Smith NVK. Effects of Clonidine on Anxiety Disorders. Arch Gen Psychiatry.
- Reversal of clonidine toxicity by naloxone. Niemann, James T et al. Annals of Emergency Medicine, Volume 15, Issue 10, 1229 - 1231
- Dennison, S. J. (2001). Clonidine abuse among opiate addicts. Psychiatric Quarterly, 72(2), 191-195. PMID: 11433883
- Koski, A., Ojanperä, I., & Vuori, E. (2002). Alcohol and benzodiazepines in fatal poisonings. Alcoholism: Clinical and Experimental Research, 26(7), 956-959.
- Revisiting clonidine: an innovative add-on option for attention-deficit/hyperactivity disorder. Childress AC, Sallee FR. (2012) https://www.ncbi.nlm.nih.gov/pubmed/22462040
- CLONIDINE HYDROCHLORIDE TABLETS, USP. . (n.d.). Retrieved January 27, 2018, from https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=091a191f-4380-4960-834c-0618da738403&type=display